<DOC>
	<DOCNO>NCT00382954</DOCNO>
	<brief_summary>The purpose study determine maximal tolerate dose ( MTD ) bortezomib idarubicin give combination newly diagnose AML patient &gt; 60 year relapse AML patient . Another purpose study determine dose limit toxicity associate bortezomib combination idarubicin newly diagnose AML patient &gt; 60 year relapse AML patient .</brief_summary>
	<brief_title>Phase I Using Velcade &amp; Idarubicin Elderly Relapsed AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Age : &gt; 60 year age newly diagnosed/transformed disease ; &gt; 18 year age relapse disease . AML without antecedent hematologic disorder diagnose morphologic , histochemical , cell surface marker criterion define WHO classification ( 17 ) . Newly diagnose , elderly patient consider unsuitable intensive chemotherapy induction antecedent hematologic disorder , preexist myelodysplasia , trilineage dyspoiesis , unfavorable cytogenetics , preexist comorbidities . Untreated condition meet criterion first third criterion patient diagnosis criterion 2 relapse least one successful induction therapy . ( Relapsed patient treat protocol patient without suitable donor transplant transplant option reason . ) Karnofsky performance status &gt; 60 . Adequate cardiac function evidence ejection fraction MUGA &gt; /= 40 , well evidence uncontrolled hypertension , New York Heart Class III/IV congestive heart failure , angina pectoris , ventricular dysrhythmias . Adequate renal function evidence calculated creatinine clearance &gt; /= 30ml/min ( CockcroftGault formula ) . Adequate pulmonary function evidence room air exercise saturation &gt; /= 92 DLCO &gt; /= 40 % FEV1 &gt; /= 60 % predict . Adequate liver function evidence SGOT/SGPT le 5 time ULN total Bilirubin le 2 time ULN except abnormality directly attributable leukemia . Adequate neurologic function patient must currently free active CNS leukemia evidence cytospin CSF lumbar puncture clinical suspicion CNS leukemia . As well , patient must &gt; /= grade 2 neuropathy NCI common toxicity criterion ( CTC ) , Version 3.0 . Prior anthracycline dose relapse patient must exceed 72 mg/m^2 idarubicin dose equivalent 300 mg/m^2 adriamycin . Patients must inform sign write consent . Patients acute promyelocytic leukemia . Patients uncontrolled systemic infection . Patients know HIV seropositive . Patients evidence CNS leukemia . Patients pregnant lactate . Patients primarily refractory disease unresponsive standard induction regimen . Patients new diagnosis per inclusion criterion 2 , standard induction chemotherapy would expect well tolerate preferred option opinion principal investigator . Patients relapse AML , suitable donor stem cell exist highdose chemotherapy hematopoietic stem cell transplant felt well immediate alternative . Patients clinically significant abnormality screen blood chemistry , hematology urinalysis result , judgment investigator , would impede adequate evaluation adverse event and/or response treatment , require aggressive intervention . Patients hypersensitivity Bortezomib , boron , mannitol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Relapse</keyword>
	<keyword>Elderly</keyword>
	<keyword>Velcade</keyword>
	<keyword>Idarubicin</keyword>
	<keyword>Bortezomib</keyword>
</DOC>